Edmonton, Alberta--(Newsfile Corp. - January 6, 2021) - Pacylex Pharmaceuticals, an oncology company unlocking a new approach to cancer therapy, today announced the publication in the journal Breast Cancer Research and Treatment data showing treatment with an N-myristoyltransferase (NMT) inhibitor reduces viability of cultured breast cancer cells and inhibits tumor growth in a mouse xenograft mouse model of human breast cancer.
Edmonton, Alberta--(Newsfile Corp. - January 6, 2021) - Pacylex Pharmaceuticals, an oncology company unlocking a new approach to cancer therapy, today announced the publication in the journal Breast Cancer Research and Treatment data showing treatment with an N-myristoyltransferase (NMT) inhibitor reduces viability of cultured breast cancer cells and inhibits tumor growth in a mouse xenograft mouse model of human breast cancer. Pacylex is developing this NMT inhibitor, PCLX-001, as a first in class therapy for various leukemias and lymphomas and also plans to study its effects on various solid tumors.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Pacylex is developing PCLX-001, which has very good oral bioavailability, to treat cancers low in N-myristoyltransferase 2 (NMT2)
- Data published in Nature Communications shows NMT inhibitor effective against many cancer cell lines, especially blood cancers including lymphoma and leukemia
- Newly published data expands target for treatment with an N-myristoyltransferase (NMT) inhibitor reduces viability of cultured breast cancer cells and inhibits tumor growth
Click image above to view full announcement.
About Pacylex
Pacylex is a pre-clinical pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, and is headquartered in Edmonton, Alberta, Canada. Pacylex’s technology combines new insights from Dr. Luc Berthiaume of the University of Alberta, connecting myristoylation to cancer, with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee in 2015. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling us to exploit NMTs as new clinical targets for cancer treatment. Pacylex completed GLP toxicology on PCLX-001 and expects to file soon for regulatory authorization to commence clinical studies in Canada in early 2021 in diffuse large B-cell lymphoma and solid tumors.
For more information:
Michael J. Weickert
CEO, Pacylex Pharmaceuticals, Inc.
E: Michael.weickert@pacylex.com
P: 650-218-1840
Twitter @Pacylex (https://twitter.com/pacylex)
LinkedIn (www.linkedin.com/company/pacylex-pharma)
Facebook (https://www.facebook.com/pacylex)
Reportable page: https://pacylex.reportablenews.com/pr/pacylex-targeting-cancer-with-novel-mechanism-and-precision-approach
Contacts:
Michael Weickert Ph.D
650-218-1840
michael.weickert@pacylex.com
Source: Pacylex